Atazanavir exposure is effective during pregnancy regardless of tenofovir use

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 57-64

  Colbers, Angela ^a   Hawkins, David ^b   Hidalgo Tenorio, Carmen ^c   Van Der Ende, Marchina ^d   Gingelmaier, Andrea ^e   Weizsäcker, Katharina ^f   Kabeya, Kabamba ^g   Taylor, Graham ^h   Rockstroh, Jürgen ⁱ   Lambert, John ^j   Moltá, José ^k   Wyen, Christoph ^l   Sadiq, S Tariq ^m   Ivanovic, Jelena ⁿ   Giaquinto, Carlo ^o   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF BONN   (Germany)

^j ROTUNDA HOSPITAL   (Ireland)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l UNIVERSITY OF COLOGNE   (Germany)

^m ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁿ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^o UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONGENITAL DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VIRUS LOAD; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PREGNANCY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AREA UNDER CURVE; ATAZANAVIR SULFATE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, THIRD; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84927721969     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2820     Document Type: Article

References (25)

1. Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. Am J Obstet Gynecol 2007; 197:S33-S41.
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. pp 1-225. Department of Health and Human Services. (Updated 28 March 2014. Accessed 1 April 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf
3. European AIDS Clinical Society. European guidelines for treatment of HIV infected adults in Europe. Version 7.0. (Updated October 2013. Accessed on 1 April 2014.) Available from http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf
4. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13 Suppl 2:87-157.
5. Griner R, Williams PL, Read JS, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS 2011; 25:385-394.
6. Esker S, Albano J, Uy J, et al. Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy. AIDS Patient Care STDS 2012; 26:307-311.
7. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44:989-1008.
8. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15:819-826.
9. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51:365-396.
10. van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV AIDS 2008; 3:620-626.
11. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51:639-659.
12. Eley T, Bertz R, Hardy H, Burger D. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review. Antivir Ther 2013; 18:361-375.
13. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56:412-419.
14. Ripamonti D, Cattaneo D, D'Avolio A, et al. Steady-state pharmacokinetic of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 907.
15. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011; 12:570-579.
16. Kreitchmann R, Best BM, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr 2013; 63:59-66.
17. European Medicines Agency. Reyataz. Summary of product characteristics. (Accessed 1 April 2014.) Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000494/WC500056380.pdf
18. Droste JAH, Verweij-van Wissen CPWGM, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
19. Holland DT, Difrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit 2006; 28:367-374.
20. Burger D, Teulen M, Eerland J, Harteveld A, Aarnoutse R, Touw D. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. Ther Drug Monit 2011; 33:239-243.
21. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409-2415.
22. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
23. von Hentig N, Dauer B, Haberl A, et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63:935-940.
24. Fournier C, Higgins N, Thomas R, et al. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit 2013; 35:264-269.
25. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther 2011; 16:1139-1147.